Stacked logo.png
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
February 15, 2024 18:35 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Stacked logo.png
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
February 13, 2024 01:30 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Stacked logo.png
Sosei Heptares Webinar Presentation for FY2023 Financial Results
January 22, 2024 04:30 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the...
Stacked logo.png
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
January 05, 2024 03:00 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating...
Stacked logo.png
Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 03:23 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces its President & CEO, Chris Cargill, will present at the 42nd...
Stacked logo.png
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
December 07, 2023 01:35 ET | Sosei Group Corporation
PIVLAZ™, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South KoreaPIVLAZ will become commercially available in South Korea in...
Stacked logo.png
Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
December 06, 2023 03:01 ET | Sosei Group Corporation
Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat...
Stacked logo.png
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
November 24, 2023 03:35 ET | Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesIndependent commercial analysis supports a worldwide peak sales...
Stacked logo.png
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
November 10, 2023 01:35 ET | Sosei Group Corporation
Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage...
Stacked logo.png
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023
November 10, 2023 01:30 ET | Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...